Introduction 38 39
It is now well established that there is a dysfunction of GABAergic systems in 40 the brain in schizophrenia. Early post-mortem studies have shown deficits in 41 interneurons in the neocortex and hippocampus [1] reflected by lower density of 42 hippocampal GABA uptake sites [2] . Subsequent confirmation has come from 43 observations of deficits in the GABAergic marker glutamic acid decarboxylase 44 (GAD)-1 mRNA and GAD-67 protein throughout the cortex [3] . These deficits 45 appear to be selective for subtypes of GABAergic neurons, most notably those 46 containing parvalbumin (PV), immunostaining for which is reduced in frontal cortex 47 and hippocampus in schizophrenia [4, 5] . It seems likely that these deficits contribute 48 to the cognitive disturbances in schizophrenia [6] , although it is conceivable that 49 hippocampal parvalbumin/GABA deficits may result in dopaminergic hyperfunction 50
[2] and thereby contribute to positive symptoms. 51
The pathogenic mechanisms underlying the PV deficit in schizophrenia are 52 also unclear, although it has been suggested that the GABAergic cells are intact but 53 hypofunctioning [7] . This is consistent with the fact that the PV deficit in certain 54 animal models of the disease appears to be related to a reversible effect of oxidative 55 stress [8] . We have speculated whether the PV deficit might relate to epigenetic 56 changes that could be induced by such environmental influences. One epigenetic 57 factor is that of DNA methylation occurring at cytosine residues in CpG sequences; 58 within promoter sequences this methylation can have major effects on gene 59 expression [9] . There is some evidence for dynamic effects on methylation of the PV 60 gene (PVALB) promoter sequence associated with manganese-induced neurotoxic 61 damage in the mouse hippocampus [10] ; also, we recently found a PVALB 62 hypermethylation in the hippocampus of rats undergoing subchronic phencyclidine 63 administration [11] , in which a PV immunostaining and mRNA deficits are well-64 established [12] [13] [14] [15] [16] . Additionally, a specific association between elevated PVALB 65 methylation and methamphetamine (METH)-induced psychosis was reported in 66 METH-dependent subjects compared to controls with no history of drug abuse or 67 psychiatric diagnosis [17] . 68
We hypothesise that changes in methylation of the PVALB promoter might 69 relate to PV deficits in schizophrenia. 
Statistical Analysis 109
Data obtained from the pyrosequencing were compared by unpaired t test and 110
were considered significantly relevant when p ≤ 0.05. All the analysis was done using 111 SPSS 20.0 (IBM Corp: Armonk, NY, USA). Variance analysis was used to evaluate 112 possible associations of age and sex of the patients with the methylation levels found. 113 114
Results

116
A series of samples of both frontal cortex and hippocampus from 16 control 117 subjects and 15 schizophrenia subjects (Table 1) Age was significantly different between the two groups but showed no 132 significant correlation with any methylation measure; including it as a covariate also 133 had no substantial influence on the results of the analyses above; differences in LINE-134 1 methylation remained significant as did hippocampal PVALB methylation at CpG2 135 and CpG4. 136 137 4. Discussion 138
The major findings from our study indicate a specific increase in PVALB 139 promoter methylation in the hippocampus in schizophrenia which is independent of 140 increases in a measure of global methylation in the brain. 141
To the best of our knowledge, this is the first study reporting hypermethylation 142 in PVALB promoter in schizophrenia patients; these data are supported by previously 143 identified evidence suggesting that hyperfunctional DNA methylation may be 144 responsible for deficiencies in GABAergic neurotransmission [18, 19] . As DNA 145 promoter hypermethylation can contribute to reduced gene expression, we suggest 146 that the well-established reduction in PV expression in the brain in schizophrenia may 147 be related to increased methylation of CpG sites within the gene promoter region. 148
The deficit in PV expression is much greater in the hippocampus [5] than in the cortex 149
[4], which may relate to the fact that a statistically significant hypermethylation was 150 only observed in the hippocampus. We have reported elevated methylation of an 151 equivalent sequence in the PVALB promoter of the hippocampus of rats which have 152 undergone a sub-chronic phencyclidine (PCP) regime, modelling some symptoms of 153 schizophrenia [11] and also find an elevation of CpG 2 methylation in blood-derived 154 DNA in subjects with methamphetamine-induced psychosis [17] . 155
The PVALB promoter region selected spans many transcription factor (TF) 156 binding sites including those for paired box domain gene 5 (PAX5) and cyclic AMP-157 responsive element (CREB). At CpG2 there is a recognition site for PAX5, which has 158 an important role in regulate the mid-hindbrain organisation during neurodevelopment 159 [20] [21] [22] , while at CpG4 is spanned by the binding site for CREB which possesses 160 intrinsic histone acetyltransferase activity [23, 24] although such studies inevitably rely on blood-derived DNA. 180
However, we found that the increase in PVALB methylation was unrelated to 181 the change in LINE-1 methylation, and thus it would appear that the finding in 182 PVALB is an independent effect, perhaps selective to this gene and potentially related 183 to the specific deficit in PV in the brain in schizophrenia. It was not possible to 184 determine PV expression in the samples used in the current study, and thus a direct 185 assessment of the correlation between DNA methylation and gene expression could 186
not be performed. 187
This study has some further limitations; the sample size was not large and, as 188 it is a post-mortem study, the patients were inevitably mostly elderly. There are other 189 variables associated with post-mortem studies that are difficult to control; these 190 include the post-mortem interval, although modelling this with rat brains at room 191 temperature over 96 hours has demonstrated no effect on DNA methylation [33] . • Equivalent sequence in rat brain DNA also shows increased methylation in the 214 phencyclidine model of schizophrenia. 215
• We found greater PVALB promoter DNA methylation in hippocampus of 216 post-mortem schizophrenia patients compared to control subjects. 217
• This increase in methylation is specific to a site within a transcription factor 218 binding sequence. 219
• We found hypermethylation in LINE-1 in hippocampus and prefrontal cortex 220 of schizophrenia post-mortem brains. 221
• The changes in PVALB methylation were independent of those in LINE-1. 222
• This hypermethylation may, through effects on transcription, contribute to the 223 enduring reduction in PV in schizophrenia. 224
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